X

Supply constraint of Creon® 10000 Creon® 25000 (Pancreatin)
4th July 2024

As the marketing authorisation holder and distributor of Creon® in the UK, we were notified by our third-party manufacturing partner, Abbott, of a supply constraint of Creon® (pancreatin) in the UK.

This constrained supply is due to high global demand and reaching maximum manufacturing supply output.

Creon® is a biologic product with a natural variation of its raw material and is made using a complex manufacturing process. The complexity of the process means that the ability to increase manufacturing capacity in the short-term is limited.

There is a long-term strategic initiative between Viatris and Abbott to increase the supply output of Creon® at the manufacturing facility. This work has already begun with expected completion in 2026.

During this supply constraint, we hope to be able to supply approximately 90-95% of the average monthly demand for Creon® lipase units into the market each month, until this supply constraint is resolved.

If you require additional information or have any questions, please contact customer services on 01707 853100 or via email; productenquiries@viatris.co.uk. For medical enquiries please contact our medical information team on 01707 853 000 or via email; info.uk@viatris.co.uk.

UK-CRE-2024-00006 July 2024

Viatris Connect
Keywords..

Resources

Viatris Connect is an online platform for UK healthcare professionals.

AIM:

Our aim with Viatris Connect is to ensure you are fully informed and up to date on all of our products and therapy areas.


CREATE ACCOUNT

ABOUT:

  • Across Viatris Connect you will find news, blogs, product information and webinars sharing knowledge and experience.
  • All of our patient support information is easily available to order and download at any time.
  • Please note that the website contains promotional and non-promotional material including educational content and resources to help you and your patients prescribed Creon®.

REGISTER NOW

For your practice

For your patients

You are leaving the Creon® healthcare professional website

You are now connecting to a website that is neither owned nor under the control of Viatris. Viatris is not responsible for the content of this site or any further links.
Please press OK to proceed or BACK to return to the Creon® healthcare professional website.
BACK
OK

You will now leave the Creon patient website and go to the Creon Track site where you can join the Creon Track patient support programme

Would you like to proceed to the Creon Track registration website?

OK
NO
Please continue to report suspected adverse drug reactions and device failures with any medicine or vaccine to the MHRA through the Yellow Card Scheme. It is easiest and quickest to report adverse drug reactions and device failures online via the Yellow Card website: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Alternatively, you can report via some clinical IT systems (EMIS/SystmOne/Vision/MiDatabank) or by calling the Commission on Human Medicines (CHM) free phone line: 0800-731-6789.
Adverse reactions/events and device failures should also be reported to MAH at e-mail address: pv.uk@viatris.com.

This website is intended for UK healthcare professionals. If you are a patient who has been prescribed Creon® please click here

Viatris UK Healthcare Limited (company registration number 09189103), an English company with a registered office address at 20 Station Close, Potters Bar, Hertfordshire, EN6 1TL (VAT - 421 623 781).

Creon® is indicated for the treatment of pancreatic exocrine insufficiency.

CRE-2021-0769 December 2023.

This website is owned and managed by Viatris. 

Copyright © 2023 Viatris Inc. All rights reserved.